| Literature DB >> 26842466 |
Ju-Hua Liu1,2, Yan Chen3, Michele Yuen4, Zhe Zhen5, Carmen Wing-Sze Chan6, Karen Siu-Ling Lam7,8, Hung-Fat Tse9,10,11, Kai-Hang Yiu12,13,14.
Abstract
BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular events. The aim of the study was to assess whether global longitudinal strain (GLS) provides prognostic value in these patients.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26842466 PMCID: PMC4738770 DOI: 10.1186/s12933-016-0333-5
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Clinical data of patients and Cox regression analysis in association with cardiovascular events
| Variable | Total (n = 247) | B | HR (95 % CI) | P |
|---|---|---|---|---|
| Demographic data | ||||
| Age, years | 59.8 ± 9.5 | 0.07 | 1.08 (1.03–1.13) | < |
| Female, n (%) | 120 (48.6) | 0.77 | 2.15 (0.80–5.76) | 0.13 |
| Body mass index, kg/m2 | 26.2 ± 4.8 | −0.08 | 0.93 (0.82–1.04) | 0.20 |
| SBP (mmHg) | 136.3 ± 18.7 | −0.001 | 1.00 (0.97–1.03) | 0.93 |
| DBP (mmHg) | 79.1 ± 8.8 | −0.03 | 0.97 (0.92–1.03) | 0.33 |
| Medical history | ||||
| Diabetes durations, years | 13.5 ± 8.2 | 0.03 | 1.03 (0.99–1.08) | 0.15 |
| Hypertension, n (%) | 186 (75.3) | 1.06 | 2.90 (0.67–12.6) | 0.16 |
| Hyperlipidemia, n (%) | 130 (52.6) | 1.09 | 2.96 (1.05–8.37) |
|
| Smoking, n (%) | 55 (22.3) | 0.17 | 1.19 (0.39–3.64) | 0.76 |
| Medication | ||||
| ACEI/ARB, n (%) | 134 (54.3) | 0.39 | 1.48 (0.58–3.78) | 0.42 |
| Calcium channel blocker, n (%) | 105 (42.5) | 0.57 | 1.76 (0.69–4.47) | 0.23 |
| B-blocker, n (%) | 55 (22.3) | 0.10 | 1.11 (0.36–3.37) | 0.86 |
| Biguanides, n (%) | 210 (85.0) | −0.23 | 0.80 (0.28–2.30) | 0.67 |
| Insulin (%) | 110 (44.5) | 1.09 | 2.96 (1.12–7.82) |
|
| Blood chemistry | ||||
| FBG (mmol/L) | 8.0 ± 2.5 | −0.26 | 0.77 (0.58–1.02) | 0.06 |
| HbA1c (%) | 7.8 ± 1.4 | −0.30 | 0.74 (0.49–1.13) | 0.16 |
| TG (mmol/L) | 1.4 ± 1.0 | −0.24 | 0.79 (0.43–1.45) | 0.44 |
| TC (mmol/L) | 4.5 ± 0.8 | −0.16 | 0.86 (0.50–1.48) | 0.58 |
| HDL (mmol/L) | 1.3 ± 0.4 | 0.81 | 2.25 (0.79–6.37) | 0.13 |
| LDL (mmol/L) | 2.5 ± 0.7 | −0.49 | 0.61 (0.29–1.30) | 0.20 |
| Creatinine (mmol/L) | 80.2 ± 39.2 | 0.01 | 1.01 (1.00–1.01) |
|
Italic values indicate statistically significant with P < 0.05
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor antagonist, CI confidence interval, DBP diastolic blood pressure, FBG fasting blood glucose, HbA1c hemoglobinA1c, HDL high-density lipoprotein cholesterol, HR hazard ratio, LDL low-density lipoprotein cholesterol, SBP systolic blood pressure, TC total cholesterol, TG triglyceride
Adjusted Cox regression analysis of individual echocardiography parameters for cardiovascular events
| Variable | Value (n = 247) | B | HR (95 % CI) | P |
|---|---|---|---|---|
| IVSd (cm) | 1.13 ± 0.19 | |||
| Univariate analysis | 2.01 | 7.43 (0.66–83.7) | 0.10 | |
| Adjusted clinical dataa | 1.43 | 4.17 (0.31–56.8) | 0.28 | |
| Adjusted clinical data + HbA1c | 1.87 | 6.50 (0.47–89.5) | 0.16 | |
| RWT, ratio | 0.50 ± 0.09 | |||
| Univariate analysis | −0.47 | 0.63 (0.002–171.5) | 0.87 | |
| Adjusted clinical dataa | −1.25 | 0.29 (0.001–89.3) | 0.67 | |
| Adjusted clinical data + HbA1c | 0.87 | 2.39 (0.01–783.1) | 0.77 | |
| LVMI (g/m2) | 100.7 ± 24.7 | |||
| Univariate analysis | 0.02 | 1.02 (1.00–1.03) | 0.07 | |
| Adjusted clinical dataa | 0.01 | 1.01 (0.99–1.04) | 0.29 | |
| Adjusted clinical data + HbA1c | 0.01 | 1.01 (0.99–1.04) | 0.27 | |
| LVEF (%) | 63.2 ± 4.5 | |||
| Univariate analysis | −0.08 | 0.92 (0.83–1.02) | 0.13 | |
| Adjusted clinical dataa | −0.07 | 0.94 (0.85–1.04) | 0.19 | |
| Adjusted clinical data + HbA1c | −0.08 | 0.93 (0.84–1.02) | 0.11 | |
| E/A ratio | 0.94 ± 0.31 | |||
| Univariate analysis | −2.51 | 0.08 (0.01–0.98) | 0.05 | |
| Adjusted clinical dataa | −1.05 | 0.35 (0.02–6.09) | 0.47 | |
| Adjusted clinical data + HbA1c | −1.62 | 0.20 (0.01–4.04) | 0.29 | |
| E/E′ ratio | 10.4 ± 4.5 | |||
| Univariate analysis | 0.15 | 1.16 (1.10–1.22) |
| |
| Adjusted clinical dataa | 0.14 | 1.16 (1.09–1.23) |
| |
| Adjusted clinical data + HbA1c | 0.14 | 1.15 (1.08–1.22) |
| |
| GLS (%) | −18.1 ± 2.4 | |||
| Univariate analysis | 0.27 | 1.31 (1.10–1.56) |
| |
| Adjusted clinical dataa | 0.29 | 1.35 (1.10–1.65) |
| |
| Adjusted clinical data + HbA1c | 0.33 | 1.39 (1.14–1.70) |
|
Italic values indicate statistically significant with P < 0.05
Abbreviations: Similar to Table 1, E/A ratio the ratio of peak mitral flow velocity in early and late at diastole, E/E′ ratio the ratio of early peak mitral inflow velocity to early myocardial velocity of mitral annulus at diastole, GLS global longitudinal stain, IVSd Inter-ventricular septal dimension at end-diastole, LVEF left ventricular ejection fraction, LVMI left ventricular mass index, RWT relative wall thickness
aClinical data includes age, gender, hyperlipidemia, plasma creatinine and treatment with insulin
Fig. 1Change in model Chi square with addition of HbA1c, E/E′ ratio and GLS to clinical data (including age, gender, hyperlipidemia, plasma creatinine and treatment with insulin). E/E′ ratio the ratio of early peak mitral inflow velocity to early myocardial velocity of mitral annulus at diastole, GLS global longitudinal stain, HbA1c hemoglobinA1c
Fig. 2Receiver-operating characteristic curves for prediction of cardiovascular events in patients with type 2 diabetes mellitus using E/E′ ratio and GLS. Abbreviations: Similar to Fig. 1
Fig. 3Kaplan–Meier analysis of cardiovascular event-free survival according to GLS > −17.9 % compared with GLS ≤ −17.9 % (Log rank χ2 = 6.52 P = 0.01), and E/E > 13.6 compared with E/E′ ≤ 13.6 (Log rank χ2 = 26.73 P < 0.01). Abbreviations: Similar to Fig. 1